Hereditary hemorrhagic telangiectasia is a genetic condition that affects small blood vessels and causes them to form abnormally. People with hereditary hemorrhagic telangiectasia often have frequent nosebleeds and small red or purple spots on the skin or lips, and some develop bleeding in the gut or lungs. It is lifelong, and signs usually appear in childhood or early adulthood, but not everyone will have the same experience. Serious complications like anemia, stroke, or lung bleeding can occur, and risk depends on which organs are involved. Treatment focuses on controlling bleeding, preventing complications, and screening for hidden vessel changes, and advances in care mean people often manage well with treatment.
Overview
Hereditary hemorrhagic telangiectasiaSymptoms
Hereditary hemorrhagic telangiectasia features frequent nosebleeds and tiny red spots on the lips, tongue, or fingertips that can bleed. Some people have abnormal blood vessel connections in the lungs, liver, or brain, causing shortness of breath, headaches, or strokes.
Outlook and prognosis
Most people with hereditary hemorrhagic telangiectasia (HHT) live long, active lives with regular care. Outlook depends on where abnormal vessels form and how early they’re found; treating nosebleeds, anemia, and organ malformations can prevent complications. Lifelong follow-up and family screening improve safety and quality of life.
Causes and risk factors
Hereditary hemorrhagic telangiectasia results from a single-gene change in blood-vessel development, usually autosomal dominant; new mutations occur. Biggest risk: an affected parent (50% chance). Severity tends to rise with age; pregnancy, blood thinners, and nasal trauma can exacerbate bleeding.
Genetic influences
Genetics are central in hereditary hemorrhagic telangiectasia; most cases result from inherited changes in ENG, ACVRL1, or SMAD4 genes. It’s typically autosomal dominant, so each child has a 50% chance. Genetic testing can confirm diagnosis and guide family screening.
Diagnosis
Hereditary hemorrhagic telangiectasia is diagnosed using clinical features and family history, supported by imaging for arteriovenous malformations. Genetic tests can confirm it. Many centers apply Curaçao criteria; genetic diagnosis of hereditary hemorrhagic telangiectasia helps guide screening.
Treatment and drugs
Treatment for hereditary hemorrhagic telangiectasia focuses on preventing bleeding, treating anemia, and protecting organs. Care often includes iron or transfusions, nasal therapies, laser or cautery for nosebleeds, and procedures for lung or brain AVMs. Regular follow-up matters.
Symptoms
Hereditary hemorrhagic telangiectasia (HHT) often shows up as easy bleeding and small, red spots on the skin or inside the mouth. For some, early features of Hereditary hemorrhagic telangiectasia include frequent nosebleeds that start in childhood or the teen years. Features vary from person to person and can change over time. Other signs reflect abnormal connections between blood vessels in organs such as the lungs, brain, or liver.
Frequent, spontaneous nosebleeds, often starting in childhood or teen years. They can be light or heavy and may happen during sleep or daily activities. Repeated bleeding can lead to low iron.
Tiny red or purple dots on the lips, tongue, face, or fingertips. They may fade when pressed and return when you let go. These fragile surface vessels can bleed.
Black stools, red blood in the stool, or unseen bleeding that shows up as anemia. This tends to appear in adulthood in people with Hereditary hemorrhagic telangiectasia. Bleeding can come and go.
Tiredness, shortness of breath with activity, or dizziness due to low iron from repeated bleeding. Skin may look pale, and headaches can occur. Iron treatment is often needed.
How people usually first notice Hereditary hemorrhagic telangiectasia?
People often first notice hereditary hemorrhagic telangiectasia (HHT) through frequent, hard‑to-explain nosebleeds that start in childhood or the teen years and may worsen over time. As years pass, tiny red or purple spots called telangiectasias can show up on the lips, tongue, face, or hands, prompting questions about the first signs of HHT and how HHT is first noticed. Some families recognize a pattern because several relatives have similar nosebleeds or had complications from hidden blood vessel tangles in the lungs or brain, which may lead a clinician to suggest HHT evaluation.
Types of Hereditary hemorrhagic telangiectasia
Hereditary hemorrhagic telangiectasia (HHT) has a few well-recognized genetic variants that affect blood vessels in similar ways but can differ in how and where problems show up. The main differences relate to which organs are more likely to be involved and the age when certain features appear. People may notice different sets of symptoms depending on their situation. Knowing the types of HHT can help families understand patterns and talk with their care team about screening and follow-up.
HHT type 1
This variant is linked to a higher chance of lung and brain arteriovenous malformations. Nosebleeds and small red skin spots still occur, but lung issues may show earlier.
HHT type 2
This type is more often tied to liver involvement and sometimes later onset nosebleeds. Skin telangiectasias can be prominent, while lung and brain arteriovenous malformations are somewhat less common than in type 1.
SMAD4-related HHT
This rare variant combines features of HHT with juvenile polyps in the digestive tract. People need screening for both blood vessel issues and colon polyps starting at young ages.
Other rare variants
Less common gene changes can cause HHT with broadly similar features. Testing helps confirm the diagnosis and may guide which organs to check most closely when discussing types of HHT.
What genetics can tell you about symptoms
Certain HHT gene changes, like in ENG or ACVRL1, make fragile surface blood vessels that can bleed easily, causing frequent nosebleeds and tiny red spots on the lips, tongue, or fingers. Variants affecting vessel growth can also create internal arteriovenous malformations, leading to shortness of breath, headaches, strokes, or anemia.
Causes and risk factors
Hereditary hemorrhagic telangiectasia is caused by changes in blood vessel genes, most often ENG, ACVRL1, or SMAD4. These gene changes can be inherited or new, and they are present before any early symptoms of hereditary hemorrhagic telangiectasia. If a parent has HHT, each child has a 50% chance of inheriting the condition. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Age, pregnancy, dry air, and blood thinning medicines can increase bleeding risk, while humidification and avoiding unnecessary blood thinners may help.
Environmental and biological risk factors
Hereditary hemorrhagic telangiectasia is present from birth, so risk relates to what happens around conception rather than day-to-day exposures later on. Doctors often group risks into internal (biological) and external (environmental). These risks explain who is more likely to be born with the condition and are separate from early symptoms of hereditary hemorrhagic telangiectasia, like frequent nosebleeds.
As sperm-producing cells divide throughout life, the chance of spontaneous changes slowly rises with age. This slightly increases the likelihood that a child is born with a condition that starts before birth, such as hereditary hemorrhagic telangiectasia. For any one pregnancy, the absolute risk remains low.
Hereditary hemorrhagic telangiectasia can appear in a family for the first time due to a one-time change that happens in the egg, sperm, or just after conception. This is rare and not caused by anything parents did before or during pregnancy. Once present, the condition is there from birth.
Very high doses of ionizing radiation to the ovaries or testes before conception can damage reproductive cells. There is no clear evidence that this specifically leads to hereditary hemorrhagic telangiectasia, but avoiding unnecessary exposure is standard medical practice. If you have had pelvic radiation, a preconception consult can clarify potential reproductive risks.
Unlike some chromosomal conditions, older maternal age has not been shown to raise the chance of hereditary hemorrhagic telangiectasia. Age-related risks in pregnancy mainly relate to other conditions, not this one.
Genetic risk factors
Hereditary hemorrhagic telangiectasia (HHT) is driven by changes in genes that guide how blood vessels form and repair. The main genes are ENG, ACVRL1, and SMAD4, with rare cases from GDF2; different genes can shape which organs are involved and when symptoms start. Some risk factors are inherited through our genes. HHT passes in an autosomal dominant way, so each child of an affected parent has a 50% chance to inherit the gene change.
Autosomal dominant pattern: HHT is inherited in a dominant way, so one changed copy of the gene is enough to cause the condition. If one parent has HHT, each child has a 50% (1 in 2) chance to inherit it. Signs can be mild in childhood and become clearer with age.
ENG (HHT1): Changes in the ENG gene (often called HHT type 1) are a common cause. People with HHT1 more often develop lung or brain arteriovenous malformations (AVMs). Nosebleeds may begin earlier in life.
ACVRL1 (HHT2): Variants in the ACVRL1 gene (HHT type 2) are also common. HHT2 is linked to a higher chance of liver AVMs and slightly later nosebleeds. Other features overlap with HHT1.
SMAD4 overlap syndrome: Rare SMAD4 variants cause a combined picture of HHT and juvenile polyposis. People may have nosebleeds plus multiple intestinal polyps and need earlier bowel screening. Some also have enlargement of the aortic root that needs monitoring.
GDF2 (BMP9): Rare changes in GDF2 can lead to an HHT-like form of the condition. Symptoms can be milder or appear later, and genetic testing helps confirm the cause. Family screening is still important when a variant is found.
Undetected gene locus: Some families meet clinical criteria for HHT but no gene change is identified on current tests. This likely reflects yet-to-be-found genes such as the historical HHT3 and HHT4 regions. The condition can still pass from parent to child.
Affected first-degree relative: Having a parent, sibling, or child with confirmed HHT is the strongest genetic risk. Each first-degree relative has a 50% chance to carry the family’s variant. Testing the known family variant shows who needs screening for AVMs.
New de novo variant: Occasionally, HHT arises in someone with no family history due to a new genetic change. Risk to siblings is usually low, but rare parental mosaicism can increase it. Children of the affected person still have a 50% chance to inherit the variant.
Age-related penetrance: HHT features become more obvious with age, so a normal exam in childhood does not rule it out. By adulthood many carriers show telangiectasia or AVMs, but severity varies widely. This can shape when early symptoms of hereditary hemorrhagic telangiectasia are noticed.
Lifestyle risk factors
Hereditary hemorrhagic telangiectasia (HHT) is a genetic condition; lifestyle habits do not cause it, but they can influence bleeding, anemia, and complications. Understanding how lifestyle affects Hereditary hemorrhagic telangiectasia can help you reduce nosebleeds, maintain iron levels, and stay active more safely. Below are lifestyle risk factors for Hereditary hemorrhagic telangiectasia that may worsen symptoms or, when adjusted, help with control.
Alcohol can dilate blood vessels and impair platelets, which may trigger or worsen nosebleeds and gastrointestinal bleeding in HHT. Limiting or avoiding alcohol can reduce bleeding episodes and iron loss.
Ongoing bleeding in HHT often causes iron deficiency and fatigue. Prioritizing iron-rich foods (e.g., red meat, legumes, leafy greens) with vitamin C–containing foods can support iron stores and energy.
Medications like ibuprofen, naproxen, and aspirin can increase bleeding by affecting platelets and mucosal integrity. Choosing non-NSAID pain options when possible may lower epistaxis and GI bleeding risk.
Nose picking and forceful nose blowing can tear fragile telangiectasias and provoke significant epistaxis. Gentle saline rinses and careful nose care can lower bleed frequency.
Risk prevention
You can’t prevent hereditary hemorrhagic telangiectasia itself, but you can lower the chance of bleeding and serious complications. Prevention works best when combined with regular check-ups. Knowing early symptoms of hereditary hemorrhagic telangiectasia—like frequent nosebleeds or iron deficiency—can prompt earlier screening and care. Plans should be tailored with your care team and updated over time.
Screening for abnormal blood vessel connections in the lungs, brain, and liver helps catch risks early. Tests are usually done at diagnosis and repeated over time, especially if symptoms change.
Closing lung AVMs (often by a catheter-based procedure) lowers the risk of stroke and brain infection. Ask about re-checking for new or recurrent AVMs after treatment.
If you have untreated or residual lung AVMs, antibiotics before dental work can lower the chance of a brain abscess. Request air filters on IV lines and avoid injecting air with any medical procedure.
Daily saline spray or gel, room humidification, and gentle nasal care can reduce bleeding triggers. An ENT familiar with HHT can offer treatments to protect the lining and limit frequent nosebleeds.
Transmission
Hereditary hemorrhagic telangiectasia (HHT) is inherited, not contagious—you can’t catch it from someone and it doesn’t spread through contact, air, or blood. If a parent has HHT, each child has a 50% (1 in 2) chance of inheriting the condition, whether the parent is the mother or father. In some families, HHT appears for the first time because of a new genetic change, so there may be no prior family history. Because of the genetic transmission of hereditary hemorrhagic telangiectasia, relatives often consider genetic counseling and testing to understand how HHT is inherited.
When to test your genes
Consider genetic testing if you have frequent nosebleeds, small red/purple skin spots, unexplained anemia, a family history of HHT, or relatives with arteriovenous malformations. Testing helps confirm diagnosis, guide screening for lung/brain/liver AVMs, and inform treatment and pregnancy planning. First test an affected family member; then offer targeted testing to relatives.
Diagnosis
For many, the first clues are frequent nosebleeds or tiny red spots on the lips, tongue, or fingertips that bleed easily. Diagnosis is usually based on recognizable clinical features and then confirmed with targeted tests that look for abnormal blood vessel connections. A detailed family and health history can help pull the picture together and guide next steps. When a specific gene change is found, it provides a clear genetic diagnosis of hereditary hemorrhagic telangiectasia and helps with screening relatives.
Doctors look for a pattern of frequent nosebleeds, typical small red spots (telangiectasias) on the skin or mouth, and evidence of internal vessel malformations. The combination of these findings strongly supports the diagnosis of hereditary hemorrhagic telangiectasia.
Providers ask about similar symptoms in parents, siblings, and children across generations. A close relative with confirmed hereditary hemorrhagic telangiectasia increases the likelihood and helps classify your own findings.
A blood or saliva test looks for changes in genes commonly linked to HHT. A positive result confirms the condition and can guide screening for family members.
An ENT specialist may use a small scope to look inside the nose for fragile, bleeding-prone vessels. Visible telangiectasias on the lips, tongue, face, or fingertips add important clinical evidence.
Stages of Hereditary hemorrhagic telangiectasia
Hereditary hemorrhagic telangiectasia does not have defined progression stages. Symptoms and risks can vary widely—from frequent nosebleeds to organ blood vessel changes—and they don’t usually follow a steady, step-by-step course. Early symptoms of hereditary hemorrhagic telangiectasia often include frequent nosebleeds and small red spots on the lips, mouth, or fingertips; doctors also consider family history and may use a simple checklist of features to make the diagnosis, sometimes confirming it with genetic testing. Different tests may be suggested to help find hidden blood vessel connections (AVMs) in the lungs, brain, or liver, and monitoring can include blood counts, iron levels, and imaging when needed.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with hereditary hemorrhagic telangiectasia (HHT), life expectancy is near normal with good care, especially when problem areas are found and treated early. Regular nosebleeds and iron‑deficiency anemia tend to be the most visible, day‑to‑day issues; early symptoms of hereditary hemorrhagic telangiectasia often include frequent nosebleeds that lead to fatigue from low iron. The bigger health risks come from abnormal blood vessel connections (called AVMs) in organs like the lungs, brain, or liver. When these are identified and managed—often with imaging, targeted procedures, and iron or blood transfusion support—the risk of stroke, severe bleeding, brain abscess, or heart strain drops substantially.
Prognosis refers to how a condition tends to change or stabilize over time. Outcomes vary based on where AVMs are located, how many there are, and how quickly they’re found. Lung and brain AVMs can be treated to prevent complications; liver AVMs are managed to reduce high‑output heart failure or portal hypertension. Serious complications and early death are uncommon in centers experienced with HHT, but they can occur if AVMs go undetected or bleeding is not controlled. Pregnancy is usually safe with planning, though people with HHT benefit from screening and care at a center familiar with the condition.
With ongoing care, many people maintain work, school, and family routines with only periodic adjustments. Screening at diagnosis—and repeated at intervals—offers the best protection against silent AVMs. Talk with your doctor about what your personal outlook might look like. Ask about early warning signs and what steps to take if they appear, such as sudden shortness of breath, new severe headache, or signs of stroke. Genetic testing can sometimes provide more insight into prognosis, since different HHT gene changes can be linked to different patterns of AVMs.
Long-term effects
Day-to-day, many living with hereditary hemorrhagic telangiectasia notice that bleeding episodes and fatigue can shape plans, work, and travel. Over years, small fragile blood vessels can appear in new places, and deeper vessel changes may lead to organ strain or complications. Long-term effects vary widely, and they can change across childhood, adulthood, and later life. Doctors often describe these as long-term effects or chronic outcomes.
Nosebleeds are often among the early symptoms of hereditary hemorrhagic telangiectasia and can persist or worsen over time. Ongoing blood loss may lead to iron deficiency and tiredness.
Small red or purple spots on the lips, tongue, face, or hands may increase in number with age. These fragile vessels can bleed with minor bumps or brushing teeth.
Abnormal connections in the lungs can lower oxygen levels and allow clots or bacteria to bypass filters. Over time, this raises risks of stroke or brain abscess in people with HHT.
Malformed vessels in the brain may stay stable or change slowly. They can sometimes lead to headaches, seizures, or bleeding events.
How is it to live with Hereditary hemorrhagic telangiectasia?
Living with hereditary hemorrhagic telangiectasia often means planning around unpredictable nosebleeds and monitoring for hidden blood vessel changes, while still finding a steady rhythm for work, school, travel, and exercise. Many manage fatigue from iron-deficiency anemia and keep regular checkups to prevent complications in the lungs, brain, or liver, and that vigilance can feel like a part-time job at times. Family members may share the condition, so conversations about genetic testing, screening, and emergency plans become part of home life, and partners or caregivers often learn simple supports like first-aid for nosebleeds and helping track iron intake. With a knowledgeable care team, preventive screenings, and practical routines, most people build a safe, full life that leaves room for spontaneity without losing sight of safety.
Treatment and drugs
Treatment for hereditary hemorrhagic telangiectasia (HHT) focuses on preventing bleeding, managing anemia, and protecting organs affected by abnormal blood vessels. Nosebleeds are the most common issue; care often starts with moisturizing nasal gels or sprays, humidification, and cautery, and may include medicines applied in the nose or, in some cases, anti‑angiogenic drugs to reduce bleeding. Iron replacement by mouth or intravenous infusion is common, and blood transfusions are used if anemia is severe; doctors also screen for and treat hidden bleeding in the gut or lungs. Lung and brain arteriovenous malformations are addressed with procedures such as catheter‑based embolization or surgery to lower the risk of stroke, brain bleed, or low oxygen, and antibiotics before certain dental or surgical procedures may be recommended to reduce infection risk if lung malformations are present. Treatment plans often combine several approaches, and regular follow‑up with an HHT center or a team familiar with HHT helps tailor care over time.
Non-drug treatment
Daily life with hereditary hemorrhagic telangiectasia often centers on preventing and managing bleeding, especially nosebleeds, and staying ahead of hidden blood vessel changes in the lungs, brain, and digestive tract. Alongside medicines, non-drug therapies can lower bleeding risk, support healthy blood levels, and reduce complications. Early symptoms of hereditary hemorrhagic telangiectasia—like frequent nosebleeds or small red skin spots—can guide which options to try first. Plans are individualized and may change over time as needs shift.
Sit up, lean forward, and pinch the soft part of the nose firmly for 10–15 minutes without checking. Use a cool compress on the bridge of the nose and breathe through the mouth. Seek urgent care if bleeding is heavy or won’t stop.
Run a bedside humidifier and use saline sprays or gels to keep the nasal lining moist. Moist tissue tears less and may bleed less often. Clean the device regularly to prevent mold or germs.
Apply a thin layer of a non-fragranced gel or ointment inside the nostrils with a clean finger or cotton swab. This reduces friction and protects fragile surface vessels in HHT. Reapply after bathing and before sleep.
In-office cautery or laser can seal fragile nasal vessels and reduce nosebleed frequency. Sessions are quick but may need repeating. An HHT-experienced ENT can tailor the settings and areas treated.
Your genes may have an impact on how drugs work for you
Genes can affect how people with hereditary hemorrhagic telangiectasia respond to drugs that control bleeding, blood vessel growth, or iron levels—changing how well they work and the risk of side effects. This is why clinicians sometimes adjust doses or choose alternatives based on family patterns and, when available, pharmacogenetic testing.
Pharmacological treatments
For many living with hereditary hemorrhagic telangiectasia (HHT), the day-to-day goal is to reduce bleeding, prevent anemia, and keep energy up. Not everyone responds to the same medication in the same way. Doctors often mix home measures, procedures, and medicines, adjusting over time to match your bleeding pattern and overall health. Below are medicines commonly used to manage nosebleeds, gut bleeding, and iron loss in HHT.
This antifibrinolytic helps blood clots hold together, which can lessen nosebleeds and some gastrointestinal bleeding. It is taken by mouth and may cause nausea or muscle cramps in some people. It is one of the better-studied medications for nosebleeds in hereditary hemorrhagic telangiectasia.
This is another antifibrinolytic option for people who cannot take tranexamic acid. It works similarly to stabilize clots and may reduce epistaxis or menstrual blood loss. Caution is needed if you have a history of blood clots.
This anti-VEGF therapy can reduce severe, recurrent nosebleeds or intestinal bleeding and lower transfusion needs. It is given by infusion with monitoring for high blood pressure and protein in the urine. It may impair wound healing and is avoided during pregnancy.
This anti-angiogenic drug can shrink fragile surface vessels and decrease epistaxis or gut bleeding. Side effects can include sleepiness, constipation, nerve damage, and blood clots, and strict pregnancy prevention is required. Ask your doctor why a specific drug was recommended for you.
Genetic influences
In most families, hereditary hemorrhagic telangiectasia (HHT) is passed down: if a parent has HHT, each child has a 1 in 2 (50%) chance of inheriting it. The gene changes involved affect how blood vessels grow and repair, which can lead to fragile surface vessels and deeper vessel tangles in organs. Even with the same gene change, people can have very different symptoms and ages of onset, so early symptoms of hereditary hemorrhagic telangiectasia may be missed in childhood and show up later. A new (de novo) change can occur in a child without any prior family history, although this is less common. Genetic testing can confirm the cause in many people with HHT and helps guide screening of relatives for problems in the lungs, brain, or liver. Knowing the genetic cause helps doctors tailor monitoring and care for you and your family.
Is Hereditary hemorrhagic telangiectasia genetic?
Genetics are central in hereditary hemorrhagic telangiectasia; most cases result from inherited changes in ENG, ACVRL1, or SMAD4 genes. It’s typically autosomal dominant, so each child has a 50% chance. Genetic testing can confirm diagnosis and guide family screening.
Pharmacogenetics—how genetics influence drug effects
In hereditary hemorrhagic telangiectasia (HHT), the specific gene subtype can shape which organs are most affected, and that often guides which treatments are likely to help and what to watch closely. For example, people with more liver involvement may be candidates for anti‑angiogenic medicine such as bevacizumab, while prominent lung vessel tangles are usually managed with procedures rather than drugs, and a subtype linked with digestive polyps prompts earlier endoscopy and iron therapy. Beyond tailoring care to organ involvement, pharmacogenetics also matters for medicines used alongside HHT care—particularly blood thinners and antiplatelet drugs if they’re ever needed for heart or clotting conditions. Genetic testing can sometimes identify how your body handles warfarin or clopidogrel, helping your team choose the right drug and dose to balance bleeding and clotting risks. When early symptoms of hereditary hemorrhagic telangiectasia lead to genetic testing, those results can also guide medication choices and monitoring plans over time, especially around surgery, pregnancy, or when new prescriptions are added.
Interactions with other conditions
Living with hereditary hemorrhagic telangiectasia (HHT) often intersects with other health issues, especially those involving the heart, lungs, and blood. Chronic nosebleeds and gut bleeding can lead to iron‑deficiency anemia, which may worsen tiredness and make shortness of breath from lung blood‑vessel malformations feel more intense. Lung AVMs raise the risk of stroke and brain abscess, particularly after dental infections, and they can make decisions about blood thinners tricky if someone also has a heart rhythm problem or a history of clots because these medicines can increase bleeding. Doctors call it a “comorbidity” when two conditions occur together. Liver AVMs can strain the heart and contribute to high‑output heart failure and pulmonary hypertension, which may overlap with existing heart or lung disease and complicate treatment plans. There’s also a recognized genetic overlap between HHT and juvenile polyposis when the SMAD4 gene is involved, so people in these families may need earlier or more frequent bowel screening due to polyp and cancer risks. Because early symptoms of hereditary hemorrhagic telangiectasia can look like common issues such as frequent nosebleeds, other conditions may be missed at first, so coordinated care and routine dental, heart, and brain evaluations can help catch interactions early.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described frequent nosebleeds that “ran in families,” with relatives across generations sharing the same tendency. Some remembered a grandparent who kept handkerchiefs nearby, or an aunt who bruised easily and tired after minor bleeding. These community stories often pointed to the condition we now call hereditary hemorrhagic telangiectasia (HHT), even before doctors had a name for it.
First described in the medical literature as clusters of tiny, fragile blood vessels on the skin and inside the nose and mouth, HHT was initially pieced together from patterns: nosebleeds starting in childhood, small red spots that blanched with pressure, and a family history of similar issues. Early reports also noted serious complications—like shortness of breath or stroke—long before the hidden cause, abnormal connections between arteries and veins, was fully understood.
From these first observations, physicians gradually recognized that HHT could affect more than the nose and skin. Reports from the late 19th and early 20th centuries linked the condition to arteriovenous malformations in the lungs, liver, and brain. Over time, descriptions became more precise, separating HHT from other bleeding disorders and setting the stage for agreed-on clinical criteria. This helped doctors identify people with HHT earlier, including those without obvious skin findings.
In recent decades, knowledge has built on a long tradition of observation. Advances in imaging confirmed internal malformations that had been suspected for years. Families and clinicians worked together to map inheritance patterns, showing that HHT often passes from parent to child. Genetic discoveries then clarified several key genes involved in blood vessel growth and repair, explaining why vessels in HHT can behave like a dimmer switch stuck too high—fragile and prone to bleeding or abnormal connections.
Despite evolving definitions, the core experience described by families—recurrent nosebleeds, visible telangiectases, and relatives with similar features—has remained central to recognizing HHT. Modern guidelines now recommend screening for lung and brain involvement, even when symptoms are mild, because early treatment can prevent complications. This shift reflects a long arc: from noticing shared symptoms at the dinner table to using targeted tests and therapies in clinic.
Looking back helps explain today’s approach to hereditary hemorrhagic telangiectasia: listen for family patterns, examine the skin and mouth, and check for silent vascular changes in critical organs. Each step in history added confidence and clarity, turning scattered stories into a reliable path for diagnosis and care.